Nodal-Region Sparing Short-Course RT With Chemo-PD-1/Bevacizumab vs. Short-Course RT With Chemotherapy as TNT in pMMR/MSS Locally Advanced Rectal Cancer

NCT07674732 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

76

Enrollment

OTHER

Sponsor class

Conditions

Short-course Radiotherapy Plus Chemotherapy
Nodal-Region Sparing Short-Course Radiotherapy Followed by Sequential Chemotherapy With PD-1 Monoclonal Antibody and Bevacizumab

Interventions

OTHER: Short-course Radiotherapy plus Chemotherapy
OTHER: Nodal-Region Sparing Short-Course Radiotherapy Followed by Sequential Chemotherapy With PD-1 Monoclonal Antibody and Bevacizumab

Sponsor

Dechang Diao